Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review.
Peripheral T-cell lymphoma (PTCL) is a disease with poor prognosis and limited treatment options. Recent advances in cancer biology suggest that PTCL may be characterized by gross epigenetic dysregulation, which may help explain its sensitivity to histone deacetylase (HDAC) inhibitors. HDAC inhibitors have demonstrated significant activity in T-cell neoplasms and recently, the BELIEF trial evaluated belinostat leading to its approval in the US. This review discusses the development of belinostat, its mechanism of action, pivotal clinical trials, drug toxicity and its recent approval for patients with relapsed or refractory PTCL. Key clinical trials covered include phase I/II evaluation of belinostat in hematologic malignancies, cutaneous T-cell lymphoma (CTCL) and PTCL. In addition, the BELIEF trial in PTCL leading to FDA approval of belinostat is reviewed in detail.
Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, 51 West 51st - Suite 200, New York, NY 10019, USA.
Ahmed
A
Sawas
Western Diagnostic Pathology & Joondalup Health Campus, 60 Shenton Avenue, Joondalup, Western Australia, Australia.
Dejan
D
Radeski
Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, USA.
Owen A
OA
O'Connor
PXD101; belinostat; histone deacetylase inhibitors; peripheral T-cell lymphoma